Pinealon — Pineal Tripeptide Bioregulator

Discovery and Origin

Pinealon — formally denoted by its amino-acid sequence Glutamic acid–Aspartic acid–Arginine (Glu-Asp-Arg, sometimes abbreviated EDR) — emerged from the St Petersburg Institute of Bioregulation and Gerontology in the mid-to-late 2000s as part of the prolific peptide-bioregulator programme led by Vladimir Khavinson and his collaborators. Khavinson's group had already produced Epithalon (Ala-Glu-Asp-Gly) and a broad family of short peptides derived from organ-specific extracts, operating on the hypothesis that short peptides could transfer biological information between tissues and reset age-related declines in gene expression.

Pinealon was designed, or isolated through fractionation studies, with the pineal gland specifically in mind. The rationale was straightforward: pineal mass and melatonin synthesis capacity decline markedly with age, and this decline correlates with disrupted circadian rhythm, impaired sleep architecture, and—through downstream serotonergic pathways—reduced neuroprotection across the broader central nervous system. By delivering a bioregulator peptide derived conceptually from pineal tissue fractions, Khavinson's team aimed to assess whether such a tripeptide could partially restore pineal function or at minimum exert neuroprotective effects in aged and oxidatively stressed neural tissue.

Early characterisation work confirmed the molecular weight of approximately 418.4 Da — small enough to fall within the theoretical window for blood-brain barrier (BBB) penetration without carrier systems — and initial in-vitro studies examined effects on neuronal cell cultures under oxidative stress conditions [PMID:16342609].

---

Mechanism of Action

Blood-Brain Barrier Penetration

Pinealon's most pharmacologically significant property is its apparent ability to cross the BBB intact. Tripeptides of Glu-Asp-Arg's molecular size can exploit endogenous peptide transport systems, including members of the PEPT family, though the precise transporter remains incompletely characterised. What the published animal-model data collectively suggest is that systemically administered Pinealon reaches neural tissue in biologically active concentrations sufficient to alter gene expression — a conclusion drawn from mRNA endpoint analyses in rodent brain regions rather than from direct pharmacokinetic tracing in humans [PMID:17655498].

Pineal and Indoleamine Modulation

Within pineal tissue, Pinealon has been linked to upregulation of enzymes involved in melatonin synthesis — notably arylalkylamine N-acetyltransferase (AANAT) — in aged animal preparations where these enzymes are markedly downregulated compared with young controls. The net effect observed in some rodent models is partial restoration of nocturnal melatonin amplitude without the ceiling-effect blunting seen with exogenous melatonin supplementation. Because melatonin itself is a potent free-radical scavenger and indirect antioxidant (upregulating superoxide dismutase and catalase), downstream neuroprotection from enhanced endogenous melatonin production is one plausible mechanism linking Pinealon administration to the neuroprotective endpoints described in rodent studies [PMID:18837027].

Neuroprotection in Oxidative-Stress Models

Independent of melatonin-centric pathways, Pinealon has demonstrated direct anti-apoptotic properties in neuronal cell-culture systems exposed to hydrogen peroxide or glutamate-induced excitotoxicity. Sibarov and colleagues reported that Glu-Asp-Arg treatment reduced caspase-3 activation and preserved mitochondrial membrane potential in cortical neuron cultures following oxidative challenge — findings consistent with either direct peptide-receptor interactions at neuronal surfaces or intracellular signalling modulation following cellular uptake [PMID:23157257]. The precise receptor or intracellular target has not been crystallographically defined; Khavinson's group proposes that short bioregulator peptides may bind DNA regulatory regions directly, acting as transcriptional modulators rather than classical receptor ligands.

---

Researched Applications

Age-Related Spatial Memory Decline

The most cited animal-model application for Pinealon involves spatial memory tasks in aged rats. Goncharova and colleagues used Morris water-maze protocols to assess spatial learning in old Wistar rats before and after ten-day subcutaneous Pinealon courses. Treated animals showed statistically significant improvements in latency to locate the hidden platform and in probe-trial recall compared with aged vehicle-treated controls, with performance approaching (but not fully matching) that of young controls [PMID:24380621]. The investigators attributed improvements to a combination of restored cholinergic tone in the hippocampus and reduced oxidative damage to CA1 pyramidal neurons, both indexed via post-mortem immunohistochemistry.

Ischaemic Stroke Models

A separate line of investigation explored Pinealon as a neuroprotective adjunct in middle cerebral artery occlusion (MCAO) rodent models. When administered subcutaneously within hours of induced ischaemia, Pinealon treatment was associated with reduced infarct volume measured at seventy-two hours post-occlusion and with better neurological deficit scores compared with saline controls. The proposed mechanism involves attenuation of ischaemia-driven oxidative burst and reduction of pro-inflammatory cytokine expression — specifically IL-1β and TNF-α — in the peri-infarct penumbra [PMID:25543952]. These findings are preliminary and have not been replicated in larger-animal models or translated to human trials.

Cognitive-Axis and Circadian Research

A smaller body of work has examined Pinealon's influence on the hypothalamic-pituitary-adrenal axis in aged animals, finding modest reductions in basal corticosterone, and on circadian rhythm parameters, where treated aged animals showed partial re-entrainment of locomotor rhythms to light-dark cycles compared with vehicle-treated counterparts. Researchers have framed these findings within the broader context of the neuroendocrine theory of ageing, in which pineal decline drives HPA dysregulation and accelerates cognitive deterioration — a framework championed by Anisimov's group and the Khavinson institute [PMID:19434547].

---

Dosing Protocols

All dosing information derives from animal-model research and the clinical-use patterns reported in Russian-language gerontological literature. No randomised controlled human trials have been published in indexed international journals. Typical parameters reported are:

• Subcutaneous (SC): approximately twenty milligrams per day, divided across one or two injections, for a ten-day cycle. Cycles are typically administered twice yearly (biannual) in the aged-animal longevity models, mirroring the Epithalon and Vilon dosing conventions established by Khavinson's group.
• Oral: Some Russian-market formulations are marketed as oral capsules. Oral bioavailability of intact peptide is expected to be low given gastrointestinal protease activity; no pharmacokinetic data comparing SC to oral Pinealon in humans exist.
• Frequency: Biannual ten-day courses are the convention drawn from animal longevity and cognition studies. Some self-experimenting users report quarterly cycles, though no comparative data support this modification.

---

Safety and Tolerability

Published toxicology data on Pinealon are sparse and limited to rodent acute-dose assessments. No serious adverse events attributable to Pinealon have been formally reported in the indexed literature. The theoretical safety concerns relevant to any subcutaneously administered research peptide apply: injection-site reactions, risks from non-sterile preparation, unknown long-term endocrine effects from sustained pineal pathway modulation, and the absence of human pharmacovigilance data. Because Pinealon modulates melatonin synthesis pathways, caution is warranted in individuals already taking pharmacological doses of exogenous melatonin or serotonergic agents, given the potential for additive or unpredictable interactions. Pregnancy and lactation contraindications apply in the absence of safety data.

---

UK Regulatory Status

Pinealon is not licensed as a medicinal product in the United Kingdom and has not received a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA). The Khavinson Institute's related bioregulator portfolio — including Epithalon, Vilon, and Cortexin — holds medicinal-product registration in the Russian Federation under frameworks applicable to peptide preparations; Pinealon's status within that Russian framework varies depending on formulation and should be independently verified. In the UK, supply of Pinealon for human use without a valid marketing authorisation may constitute an offence under the Human Medicines Regulations 2012. Research and laboratory use for non-clinical purposes is subject to separate licensing considerations. Buyers should obtain current regulatory guidance before purchase or importation.

---

Reconstitution

Pinealon is supplied as a lyophilised (freeze-dried) powder, typically in vials of two to ten milligrams. Standard reconstitution practice for research use involves:

• Adding bacteriostatic water (preferred for multi-dose vials) or sterile water for injection at a rate to yield a working concentration of approximately one to two milligrams per millilitre.
• Swirling gently — never vortexing — until the powder is fully dissolved.
• Storing reconstituted vials refrigerated at two to eight degrees Celsius and discarding unused solution after twenty-eight days (bacteriostatic water) or within twenty-four hours (plain sterile water).
• Lyophilised unreconstituted vials should be stored at minus twenty degrees Celsius and shielded from light.

Because Pinealon contains arginine and aspartic acid residues susceptible to oxidation under warm or light-exposed conditions, cold-chain integrity during storage and shipping is important for maintaining peptide integrity.

---

Frequently Asked Questions

Does Pinealon increase melatonin? Animal-model data suggest Pinealon can partially restore age-suppressed melatonin biosynthesis by upregulating AANAT and related enzymes in pineal tissue. It does not appear to deliver exogenous melatonin or act as a direct melatonin-receptor agonist. Whether the same effect occurs in humans is unknown.

Can Pinealon be taken orally? Some commercial preparations are marketed as oral capsules, predominantly within the Russian market. Oral bioavailability of intact Glu-Asp-Arg is expected to be limited; injectable subcutaneous routes are used in the research literature for assured systemic delivery.

How does Pinealon differ from Epithalon? Both are Khavinson-group bioregulators with anti-ageing and neuroprotective research profiles, but they differ in sequence, length, and primary tissue targets. Epithalon (tetrapeptide Ala-Glu-Asp-Gly) is most studied in the context of telomere biology and epiphyseal/thymus function; Pinealon is a tripeptide targeted specifically at pineal modulation and direct neuroprotection.

Is Pinealon the same as melatonin? No. Melatonin is an indole hormone synthesised endogenously from serotonin. Pinealon is a synthetic tripeptide that may influence the enzymatic pathways producing melatonin but is chemically unrelated.

What stacks pair well with Pinealon for nootropic research? In preclinical literature and among researchers exploring neuroprotective peptide combinations, Pinealon is sometimes considered alongside BBB-penetrant neuropeptides with complementary mechanisms. See the Semax–Selank–Pinealon Nootropic Stack for a detailed protocol overview.

Source research-grade Pinealon

Pinealon — Pineal Tripeptide Bioregulator is sold for laboratory and in vitro research use only. UK regulatory status: Khavinson group has medicinal-product approval for related bioregulators in the Russian Federation. Pinealon itself remains an unapproved research compound in UK, US, EU..

Source on PeptideBarn.co.ukFull monograph on PeptideAuthority.co.uk